Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sitravatinib + tislelizumab
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Sitravatinib + tislelizumab is an investigational combination therapy for various advanced cancers. Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM receptors (TYRO3, AXL, MER), VEGFR-2, KIT, and MET. Tislelizumab is an anti-PD-1 monoclonal antibody. This combination aims to enhance antitumor immune responses by increasing tumor antigen presentation, promoting lymphocyte infiltration and migration, reducing myeloid-derived suppressor cells (MDSCs), and increasing the ratio of M1/M2-polarized macrophages. The combination has shown promising antitumor activity in multiple cancer types, including biliary tract cancer, non-small cell lung cancer, hepatocellular carcinoma, gastric/gastroesophageal junction cancer, and melanoma, particularly in patients with anti-PD-(L)1 resistant/refractory disease.
- Brand names
- Tevimbra
- Other names
- odronextamab-rvfx-BeiGene-hepatocellular carcinoma
02
Targets
AXL (AXL receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)MET (Mesenchymal-epithelial transition factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on sitravatinib + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sitravatinib + tislelizumab.